伊班膦酸钠联合治疗类固醇性骨质疏松症26例临床观察

Clinical Observations of Ibandronate Combined with Calcium Carbonate D3 and Calcitriol in 26 Patients with Glucocorticoid-induced Osteoporosis

目的探讨伊班膦酸钠联合碳酸钙D3片及骨化三醇胶丸治疗类固醇性骨质疏松症的安全性及疗效。方法对26例类固醇性骨质疏松症患者进行前后自身对照研究。患者年龄31～76(平均52±4.6)岁,口服碳酸钙D3片0.6 g/d,骨化三醇胶丸0.25μg,每隔3个月静脉滴注伊班磷酸钠2 mg,总疗程l2个月,对比治疗前后的骨密度变化。结果治疗12个月后,患者腰椎、股骨颈、大转子及Ward's三角骨密度显著增加(均P<0.05),增幅分别达6.5%、4.3%、3.8%及3.2%。结论伊班磷酸钠联合碳酸钙D3片及骨化三醇胶丸治疗类固醇性骨质疏松症安全、有效、方便。

Objective To observe the safety and effects of Ibandronate combined with Calcium carbonate D3 and Calcitriol in patients with Glucocorticoid-induced osteoporosis.Methods 26 patients with Glucocorticoid-induced osteoporosis,aged 31-76 years old,took Calcium carbonate D3 0.6 g/d and calcitriol 0.25ug/d,and then received ibandronate 2 mg per 3 months for 12 months.Bone mineral density（BMD）were measured and compared before and after treatment.Results After 12 months of treatment BMD at lumbar,neck,torch and Ward＇s were increased significantly by 6.5%、4.3%、3.8% and 3.2%,P〈0.05.Conclusion Ibandronate combined with Calcium carbonate D3 and Calcitriol is safe,effective and convenient medication in patients with Glucocorticoid-induced osteoporosis.